Brookside Capital
Brookside Capital is a San Francisco based investment advisory firm which offers clients portfolio management, investment advisory and financial planning services.
All edits
Brookside Capital does not hold cash or securities and they do not sell assets. Instead they charge a management fee ranging from 1.5% to 0.5% per year dependent on the account size. Client assets are held at a brokerage firm.
Brookside Capital has made investments in Anaplan, Socar, SevOne, Translate Bio, Giosis, REGENXBIO, MuleSoft, DocuSign, Voyager Therapeutics, Spark Therapeutics and Zafgen.
They exited their investments in SevOne, Anaplan, Brightcove, PTC Therapeutics, FibroGen, Youku, Spark Therapeutics, DocuSign, Dicerna Pharmaceuticals, Voyager Therapeutics, Translate Bio and MuleSoft.
Brookside Capital has made investments in Anaplan, Socar, SevOne, Translate Bio, Giosis, REGENXBIO, MuleSoft, DocuSignDocuSign, Voyager Therapeutics, Spark Therapeutics and Zafgen.
Brookside Capital has made investments in Anaplan, Socar, SevOne, Translate Bio, Giosis, REGENXBIO, MuleSoft, DocuSign, Voyager TherapeuticsVoyager Therapeutics, Spark Therapeutics and Zafgen.
They exited their investments in SevOne, Anaplan, BrightcoveBrightcove, PTC Therapeutics, FibroGen, Youku, Spark Therapeutics, DocuSign, Dicerna Pharmaceuticals, Voyager Therapeutics, Translate Bio and MuleSoft.
They exited their investments in SevOne, Anaplan, Brightcove, PTC Therapeutics, FibroGen, Youku, Spark Therapeutics, DocuSign, Dicerna PharmaceuticalsDicerna Pharmaceuticals, Voyager Therapeutics, Translate Bio and MuleSoft.
Brookside Capital is a San Francisco, CaliforniaCalifornia based investment advisory firm. They offer clients portfolio management and financial planning services. Brookside Capital focuses on high net worth individuals, with an average minimum account of $1 million. They have $26.5 million in assets under management.
Brookside Capital has made investments in Anaplan, Socar, SevOne, Translate BioTranslate Bio, Giosis, REGENXBIO, MuleSoft, DocuSign, Voyager Therapeutics, Spark Therapeutics and Zafgen.
Brookside Capital has made investments in Anaplan, Socar, SevOne, Translate Bio, Giosis, REGENXBIO, MuleSoft, DocuSign, Voyager Therapeutics, Spark TherapeuticsSpark Therapeutics and Zafgen.
They exited their investments in SevOne, Anaplan, Brightcove, PTC TherapeuticsPTC Therapeutics, FibroGen, Youku, Spark Therapeutics, DocuSign, Dicerna Pharmaceuticals, Voyager Therapeutics, Translate Bio and MuleSoft.
Find more companies like Brookside Capital
